A pilot study that included 45% of primary and 55% of recurrent glioblastoma (GBM) cases with isocitrate dehydrogenase (IDH) 1/2 wild-type showed immunoexpression of p62 in the nucleus and cytoplasm of tumor components (Ieni et al. 2022). Here, IDH3A is linked to glioblastoma.